N/A
- Pharmaceuticals
- Suboxone & Methadone Treatment Market
Suboxone & Methadone Treatment Market
Suboxone & Methadone Treatment Market - Global Industry Analysis 2014 - 2018 and Forecast 2019 - 2029
Market Overview
Suboxone & Methadone Treatment is used for treating opioid dependence. Methadone has been used for opioid addiction since its launch, in 1937 in Germany. Later in 1960s it was popularly used for treating heroin addiction. While Methadone has a long history for treatment of opioid dependency, Suboxone is a relatively new product in the market.
Suboxone or Buprenorphine is a synthetic opioid and has a relatively low risk of overdose. Suboxone is available in two form, they are uncombined form and generic form. The generic form is combined with naloxone to prevent the further abuse of the drug.
While Methadone is available in the form of tablets or diskets, Suboxone are available in the form of tablets and films. Both Suboxone & Methadone Treatment must be prescribed by the doctor.
According to the law, methadone can be dispensed at an opioid treatment program that is certified by the Substance Abuse and Mental Health Services Administration and registered by the Drug Enforcement Administration, in the U.S. Suboxone & Methadone Treatment is recommended for at least 12 months. However the duration of the Suboxone & Methadone Treatment may vary from patient to patient.
According to the National Institute on Drug Abuse, over prescription of painkillers including drugs such as OxyContin, Vicodin and Heroin, lack of adequate resources for the understanding of mechanism of action and addiction, has led to the opioid epidemic with over 115 people fatally overdosing on opioids every day in the U.S. About 1.9 million people in the U.S. are estimated to be addicted to prescription opioid drugs. Increase in Opioid addition is the major factor for the surge in growth of the Suboxone & Methadone Treatment Market globally.
Regional Outlook
North America and Europe are among the leading regions in the Suboxone & Methadone Treatment market owing to the increase in awareness for drug abuse, rise in opioid addiction, increase in healthcare spending and other similar factors.
Asia Pacific region is expected to have an increase in rate of adoption for the Suboxone & Methadone Treatment sue to increasing number of awareness programs leading to higher adoption of the Suboxone & Methadone Treatment. Latin America and the Middle East and Africa region is expected to have a lower market share, however increasing adoption is expected to boost its market growth during the forecast period.
Key Players
Some of the key players operating in the Suboxone & Methadone Treatment market are Reckitt Benckiser Healthcare, Mylan Inc., Lannett Company Inc, Purdue pharma lp, Hospira inc, Mallinckrodt chemical inc, Sandoz inc, Roxane laboratories inc and Vistapharm inc among others.
The report covers exhaustive analysis on:
- Suboxone & Methadone Treatment Market Segments
- Suboxone & Methadone Treatment Market Dynamics
- Historical Actual Suboxone & Methadone Treatment Market Size, 2013 - 2017
- Suboxone & Methadone Treatment Market Size & Forecast 2017 to 2026
- Suboxone & Methadone Treatment Market Current Trends/Issues/Challenges
- Competition & Companies involved
- Suboxone & Methadone Treatment Market Drivers and Restraints
Regional analysis includes
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
Report Highlights:
- Shifting Industry dynamics
- In-depth market segmentation
- Historical, current and projected industry size Recent industry trends
- Key Competition landscape
- Strategies of key players and product offerings
- Potential and niche segments/regions exhibiting promising growth
- A neutral perspective towards market performance
